SCG Cell Therapy Pte Ltd, a biotechnology company focused on developing advanced immunotherapies, has announced the presentation of clinical results for SCG142 at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin. The data, from an investigator-initiated Phase I trial, highlights the potential of SCG142 in treating recurrent or metastatic HPV-associated carcinomas.
The ongoing trial evaluates the safety and efficacy of SCG142, a T-cell receptor-engineered therapy targeting HPV. The study involves patients with advanced HPV16- or HPV52-positive carcinomas who have not responded to previous treatments. As of the latest data, all seven patients treated showed tumour shrinkage, achieving a 100% disease control rate. Notably, four patients experienced over 30% tumour reduction, with two confirmed partial responses.
No serious adverse events or dose-limiting toxicities were reported, indicating the therapy’s tolerability. “SCG142 is a novel and differentiated HPV-specific TCR T cell therapy with promising clinical activity,” stated Prof. Dr. Yang Li, Director of Medical Oncology at The First Affiliated Hospital of Guangxi Medical University. She emphasised the potential of SCG142 to offer new treatment options for various HPV-related cancers.
SCG142 was developed using SCG’s GianTCRTM platform, which identifies high-affinity T-cell receptors. These promising results support further clinical development and evaluation in larger patient cohorts.
